Compare UVV & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | CAPR |
|---|---|---|
| Founded | 1886 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1994 | 2011 |
| Metric | UVV | CAPR |
|---|---|---|
| Price | $52.49 | $34.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.63 |
| AVG Volume (30 Days) | 156.6K | ★ 1.0M |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $2,922,924,000.00 | N/A |
| Revenue This Year | $0.67 | N/A |
| Revenue Next Year | $0.10 | $3.31 |
| P/E Ratio | $17.16 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $49.96 | $4.30 |
| 52 Week High | $67.33 | $40.37 |
| Indicator | UVV | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 65.37 |
| Support Level | $51.37 | $22.09 |
| Resistance Level | $53.87 | $36.49 |
| Average True Range (ATR) | 0.91 | 2.05 |
| MACD | -0.03 | 0.31 |
| Stochastic Oscillator | 55.91 | 85.63 |
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.